Cullinan Oncology
CGEM
113 hedge funds and large institutions have $671M invested in Cullinan Oncology in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 40 increasing their positions, 38 reducing their positions, and 18 closing their positions.
74% more capital invested
Capital invested by funds: $385M → $671M (+$286M)
36% more call options, than puts
Call options by funds: $215K | Put options by funds: $158K
3.11% more ownership
Funds ownership: 88.31% → 91.42% (+3.1%)
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
5% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 38
0% more funds holding
Funds holding: 113 → 113 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$20.8M |
| 2 |
DM
Deerfield Management
New York
|
+$17.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$13.3M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIG
American International Group
New York
|
-$18.9M |
| 2 |
Morgan Stanley
New York
|
-$10.6M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$9.03M |
| 4 |
BOCH
Blue Owl Capital Holdings
New York
|
-$7.65M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$5.43M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCP
126
GSA Capital Partners
London,
United Kingdom
| – | -$104K | -10,246 | Closed |
|
127
VOYA Investment Management
Atlanta,
Georgia
| – | -$103K | -10,061 | Closed |
|
128
Vontobel Holding
Zurich,
Switzerland
| – | -$102K | -10,000 | Closed |
|
|
PAS
129
Point72 Asia (Singapore)
Singapore
| – | -$29.1K | -2,852 | Closed |
|
130
Russell Investments Group
London,
United Kingdom
| – | -$23.4K | -2,300 | Closed |
|
|
PMEF
131
Point72 Middle East FZE
Dubai,
United Arab Emirates
| – | -$12.2K | -1,195 | Closed |
|
CGEM Hedge Fund Activity: Q1 2024 in Review
113 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q1 2024, worth a combined $671M — up 74% from $385M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CGEM positions and 18 closed out — a net gain of 1 holder — while 40 added to existing stakes and 38 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $20.8M. The largest seller was American International Group, cutting an estimated $18.9M.
- 113 institutional investors held Cullinan Oncology (CGEM) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $671M of Cullinan Oncology stock for Q1 2024, up 74% quarter-over-quarter.
- 19 funds opened new Cullinan Oncology positions in Q1 2024 and 18 closed out, a net change of +1 holder.
- The largest Cullinan Oncology buyer in Q1 2024 was Paradigm Biocapital Advisors, an estimated $20.8M added.
- The largest Cullinan Oncology seller in Q1 2024 was American International Group, an estimated $18.9M sold.
Based on aggregated 13F filings for Q1 2024.